REG - Hutchmed China Ltd - Notice of Results

HUTCHMED (China)Announcement

02/07/2021 09:35

RNS Number : 9844D
  
Hutchmed (China) Limited
  
02 July 2021
  
 

HUTCHMED to Announce 2021 Half-Year Financial Results
 
Hong Kong, Shanghai & Florham Park, NJ - Friday, July 2, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)).
 
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.  
 
The conference call and audio webcast will take place at 1:00 pm BST / 8:00 pm HKT / 8:00 am EDT on Wednesday, July 28, 2021 and will be webcast live via the company website at www.hutch-med.com/investors/event-information/.  The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website.  A replay will also be available on the website shortly after the event.
 
 
About HUTCHMED
 
HUTCHMED (Nasdaq/AIM: HCM; SEHK: 13) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
 
 
CONTACTS
 



Investor Enquiries








Mark Lee, Senior Vice President


+852 2121 8200




Annie Cheng, Vice President


+1 (973) 567 3786














Media Enquiries


 




Americas - Brad Miles, Solebury Trout


+1 (917) 570 7340 (Mobile) 
bmiles@troutgroup.com




Europe - Ben Atwell / Alex Shaw, FTI Consulting


+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com




Asia - Joseph Chi Lo / Zhou Yi, Brunswick


+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) 
HUTCHMED@brunswickgroup.com














Nominated Advisor








Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited


+44 (20) 7886 2500



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NORQLLBBFDLFBBB